Duke University

Running trials

• Not yet recruiting

  A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer

  NCT07905131· Phase 1/2· Daniel Nussbaum, M.D.· Source

• Not yet recruiting

  Addressing Barriers to Anti-hypertensive Medication Adherence Among PLWH Who Have Achieved Viral Suppression

  NCT05459077· Duke University· Source

• Not yet recruiting

  Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

  NCT07795593· Phase 4· University of Michigan· Source

• Recruiting

  A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

  NCT07830732· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Lupus Nephritis Care Pathway

  NCT07783152· Duke University· Source

• Recruiting

  INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery

  NCT06965504· Abiomed Inc.· Source

• Not yet recruiting

  Jigsawdio Multisensory Platform for People With Mild Cognitive Impairment, Alzheimer's Disease, or Related Dementias

  NCT07839286· Callahan-Young LLC DBA Jigsawdio· Source

• Not yet recruiting

  Signatera Assessment in Early-Stage Endometrial Cancer

  NCT07339384· Natera, Inc.· Source

• Not yet recruiting

  Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial

  NCT07746271· Phase 3· The George Washington University Biostatistics Center· Source

• Recruiting

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· Phase 3· CSL Behring· Source

• Recruiting

  Asciminib in HER2+ Breast Cancer Brain Metastases

  NCT07136428· Phase 1/2· Duke University· Source

• Not yet recruiting

  Improving the Quality of Care for Asthma Patients at Risk of Exacerbations

  NCT06596512· Brigham and Women's Hospital· Source

• Not yet recruiting

  Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

  NCT07601295· Phase 2· Stanford University· Source

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· Phase 3· Prilenia· Source

• Not yet recruiting

  Virtual Activities of Living for Occupational Rehabilitation

  NCT07450586· Barron Associates, Inc.· Source

• Recruiting

  A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

  NCT07428616· Phase 2· Exelixis· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

  NCT07226453· Phase 2· University of California, San Francisco· Source

• Not yet recruiting

  Occlutech AFR Fontan Study

  NCT07532369· Occlutech International AB· Source

• Recruiting

  An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

  NCT07365332· Phase 3· Inhibikase Therapeutics· Source

• Recruiting

  A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)

  NCT07282847· Phase 1/2· AskBio Inc· Source

• Recruiting

  SickleFit Exercise and Nutrition Study

  NCT07442851· Duke University· Source

• Recruiting

  Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer

  NCT07144228· Duke University· Source

• Recruiting

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· Phase 1/2· Pfizer· Source

• Recruiting

  A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

  NCT07491497· Phase 1/2· TRIANA Biomedicines, Inc.· Source

• Recruiting

  Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

  NCT07477639· Phase 1/2· Tr1X, Inc.· Source

• Recruiting

  Using PrEP, Doing It for Ourselves

  NCT06638892· Duke University· Source

• Recruiting

  Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections

  NCT07351071· Medtronic - MITG· Source

• Recruiting

  Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

  NCT07110454· Epiminder America, Inc.· Source

• Recruiting

  Diagnosing Epilepsy To EffeCT Change

  NCT07110337· Epiminder America, Inc.· Source

• Recruiting

  CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

  NCT07322094· Phase 1/2· TORL Biotherapeutics, LLC· Source

• Enrolling by invitation

  Dialysis Geriatric Care Model

  NCT05793138· Duke University· Source

• Recruiting

  Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

  NCT06816927· Phase 2· Duke University· Source

• Recruiting

  Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

  NCT06906627· Duke University· Source

• Recruiting

  Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

  NCT06906640· Duke University· Source

• Recruiting

  Characterizing the Microvascular Environment of Bladder Cancer With Super-Resolution Ultrasound Localization Microscopy

  NCT06986304· Duke University· Source

• Recruiting

  A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  NCT07221500· Phase 2· Nurix Therapeutics, Inc.· Source

• Recruiting

  Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer

  NCT06795529· Massachusetts General Hospital· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

• Recruiting

  A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

  NCT07115745· Phase 1· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Recruiting

  A Study of GNTI-122 in Adults Recently Diagnosed With T1D

  NCT06919354· Phase 1· GentiBio, Inc· Source

• Active, not recruiting

  Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)

  NCT07120945· Medtronic - MITG· Source

• Enrolling by invitation

  Enhancing Resilience Among Patients With Stroke: Implementation of High Intensity Home-based Rehabilitation

  NCT07098286· Duke University· Source

• Active, not recruiting

  A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

  NCT06985147· Phase 2· Disc Medicine, Inc· Source

• Recruiting

  COMPASS Study for Metastatic Castration-resistant Prostate Cancer

  NCT07050433· Duke University· Source

• Recruiting

  Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

  NCT06898515· Reprieve Cardiovascular, Inc· Source

• Enrolling by invitation

  Chronic Exogenous Ketosis in HFpEF

  NCT06937320· Phase 2· Duke University· Source

• Recruiting

  A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

  NCT07123038· Sonoma Biotherapeutics, Inc.· Source

• Active, not recruiting

  P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

  NCT06468033· Phase 3· PharmaEssentia· Source

• Recruiting

  Targeted Remotely-delivered Anti-inflammatory Interventions With Exercise for Rheumatoid Arthritis

  NCT06841562· Duke University· Source

Showing 50 of 215.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers12 recruiting
• Prostate cancer10 recruiting
• Heart failure9 recruiting
• Lung cancer8 recruiting
• High blood pressure6 recruiting
• Sarcoma6 recruiting
• Chronic lymphocytic leukaemia5 recruiting
• Coronary artery disease5 recruiting
• Glioblastoma5 recruiting
• Stroke5 recruiting
• Type 1 diabetes5 recruiting
• Acute myeloid leukaemia4 recruiting
• Colorectal cancer4 recruiting
• Epilepsy4 recruiting
• Lupus (SLE)4 recruiting
• Metastatic breast cancer4 recruiting
• Pulmonary arterial hypertension4 recruiting
• Rheumatoid arthritis4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Alzheimer disease3 recruiting
• Chronic kidney disease3 recruiting
• Endometrial cancer3 recruiting
• Mantle cell lymphoma3 recruiting
• Neuroblastoma3 recruiting
• Ovarian cancer3 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• ALS (motor neurone disease)2 recruiting
• Aortic aneurysm2 recruiting
• Bladder cancer2 recruiting
• Follicular lymphoma2 recruiting
• Frontotemporal dementia2 recruiting
• Head and neck cancer2 recruiting
• HIV2 recruiting
• Huntington's disease2 recruiting
• Irritable bowel syndrome2 recruiting
• Liver and biliary tract cancer2 recruiting
• Multiple myeloma2 recruiting
• Multiple sclerosis2 recruiting
• Myasthenia gravis2 recruiting
• Myelodysplastic syndromes2 recruiting
• Osteoporosis2 recruiting
• Sickle cell disease2 recruiting
• Triple-negative breast cancer2 recruiting
• Type 2 diabetes2 recruiting
• Aortic stenosis1 recruiting
• Asthma1 recruiting
• Atrial fibrillation1 recruiting
• Autism1 recruiting
• Cervical cancer1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Congenital heart disease1 recruiting
• Depression1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Dystonia1 recruiting
• Essential tremor1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Haemophilia1 recruiting
• Hidradenitis suppurativa1 recruiting
• Hodgkin lymphoma1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Insomnia1 recruiting
• Melanoma1 recruiting
• Meningioma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Obesity1 recruiting
• Obstructive sleep apnoea1 recruiting
• Pancreatic cancer1 recruiting
• Parkinson disease1 recruiting
• Polycystic ovary syndrome1 recruiting
• Pompe disease1 recruiting
• Sjögren's disease1 recruiting
• Spinal cord injury1 recruiting
• Thalassaemia1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Completed

  Assessing Better Bottles for Babies

  NCT06357299· Duke University· Source

• Completed

  Whole Health Empowerment for Endotypes of Lupus: Improving Quality of Life in SLE

  NCT06720584· Duke University· Source

• Completed

  REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

  NCT06788535· Phase 3· Sharmila Dorbala· Source

• Completed

  ABC-CT Pre-School Feasibility Study

  NCT06413316· Yale University· Source

• Terminated

  NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

  NCT06299163· Phase 1· Numab Therapeutics AG· Source

• Completed

  Ketones in Heart Failure With Reduced Ejection Fraction

  NCT06195982· Phase 2· Duke University· Source

• Completed

  Evaluation of Advanced Imaging and Visualization for Clinical Deep Brain Stimulation

  NCT06191874· Duke University· Source

• Completed

  TipTraQ Home Sleep Test Validation Study, Duke

  NCT06351878· PranaQ Pte. Ltd.· Source

• Recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

  NCT06004245· Phase 1· Vividion Therapeutics, Inc.· Source

• Completed

  Healthy Lifestyles After Cancer for Adolescents and Young Adults: A Program to Reduce Cardiovascular Risk Factors

  NCT05869604· Duke University· Source

• Completed

  Accuracy Performance Verification of the INVOS™ System in Pediatrics

  NCT05962905· Medtronic - MITG· Source

• Completed

  Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer

  NCT06145750· Delfi Diagnostics Inc.· Source

• Terminated

  Visualization of the STN and GPi for DBS

  NCT05774041· Surgical Information Sciences Inc.· Source

• Completed

  A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

  NCT05975073· Phase 1/2· Amgen· Source

• Completed

  A Feasibility Trial of OCM Supplements for the Treatment of NAFLD

  NCT05720702· Early phase 1· Duke University· Source

• Terminated

  64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

  NCT05633160· Phase 1/2· Clarity Pharmaceuticals Ltd· Source

• Completed

  Ketone Pharmacokinetic Study in HFrEF

  NCT05757193· Phase 1· Duke University· Source

• Completed

  Healthy Me: A Program for Older Women

  NCT03843190· Duke University· Source

• Completed

  Midwest TXTXT Scale up of an Evidence-Based Intervention to Promote HIV Medication Adherence

  NCT05783297· Amy K. Johnson, PhD, MSW· Source

• Completed

  AF at Home: A Virtual Education Program for Patients With Atrial Fibrillation (AF)

  NCT05810896· University of North Carolina, Chapel Hill· Source

• Completed

  A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

  NCT05686044· Phase 2/3· Annovis Bio Inc.· Source

• Completed

  Gerofit Exercise Intervention for Older Adults With Sickle Cell Disease (SICKLE-FIT Study)

  NCT05714098· Duke University· Source

• Completed

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Dissemination and Implementation of Improving Pediatric Obesity Practice Using Prompts

  NCT05627011· Yale University· Source

• Terminated

  A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

  NCT05600426· Phase 3· Boston Children's Hospital· Source

• Terminated

  Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

  NCT05068726· GE Healthcare· Source

• Completed

  Parks & Pediatrics Fit Together

  NCT05455190· Duke University· Source

• Completed

  Virtual Care to Improve Heart Failure Outcomes (VITAL-HF)

  NCT05602454· Duke University· Source

• Completed

  A Study of TAK-341 in Treatment of Multiple System Atrophy

  NCT05526391· Phase 2· Takeda· Source

• Completed

  Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

  NCT05643534· Phase 3· Ardelyx· Source

• Completed

  Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART

  NCT05604209· Phase 1· University of North Carolina, Chapel Hill· Source

• Completed

  Cognitive Disparities in Parkinson's Disease

  NCT07262658· Duke University· Source

• Completed

  Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO

  NCT05890274· University of North Carolina, Chapel Hill· Source

• Withdrawn

  ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

  NCT05481905· Phase 2· Engrail Therapeutics INC· Source

• Recruiting

  Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device

  NCT04839705· Microvention-Terumo, Inc.· Source

• Completed

  Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors

  NCT05383872· InSightec· Source

• Completed

  Motivating Occupational Virtual Experiences In Therapy for Kids

  NCT04510857· Barron Associates, Inc.· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Completed

  Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

  NCT04972097· Angiodynamics, Inc.· Source

• Completed

  A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

  NCT04987489· Phase 2· Forma Therapeutics, Inc.· Source

• Completed

  Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain

  NCT04906447· Phase 2· University of Illinois Chicago· Source

• Completed

  A Study of Elecsys® Troponin T hs Gen 6 in Participants With Symptoms of Acute Coronary Syndrome

  NCT06734117· Hoffmann-La Roche· Source

• Terminated

  Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

  NCT04892446· Phase 2· Gilead Sciences· Source

• Completed

  Healthy Food First

  NCT05048836· University of North Carolina, Chapel Hill· Source

• Completed

  Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings

  NCT05030272· Wake Forest University Health Sciences· Source

• Completed

  realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

  NCT04981795· Incyte Corporation· Source

• Completed

  Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening

  NCT04968548· Nucleix Ltd.· Source

• Terminated

  SPARK-ALL: Calaspargase Pegol in Adults With ALL

  NCT04817761· Phase 2/3· Institut de Recherches Internationales Servier· Source

• Completed

  Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures

  NCT04903314· Phase 1· SK Life Science, Inc.· Source

• Completed

  Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

  NCT04880434· Phase 2· Kite, A Gilead Company· Source

Showing 50 of 86.

Conditions

Diseases this institution publishes on or runs trials for.

• Heart failure325 works · 17 trials
• Stroke287 works · 13 trials
• HIV267 works · 7 trials
• Obesity242 works · 8 trials
• Alzheimer disease201 works · 9 trials
• Prostate cancer145 works · 14 trials
• Type 2 diabetes117 works · 3 trials
• Lung cancer117 works · 22 trials
• Atrial fibrillation87 works · 3 trials
• Chronic kidney disease86 works · 4 trials
• Melanoma81 works · 5 trials
• Coronary artery disease67 works · 11 trials
• Colorectal cancer67 works · 6 trials
• Osteoarthritis64 works · 8 trials
• Epilepsy63 works · 9 trials
• Parkinson disease62 works · 9 trials
• Glioblastoma60 works · 9 trials
• Glaucoma58 works · 0 trials
• Ovarian cancer56 works · 8 trials
• Sickle cell disease54 works · 10 trials
• Sarcoma44 works · 11 trials
• Childhood cancers41 works · 17 trials
• Tuberculosis40 works · 0 trials
• Osteoporosis36 works · 3 trials
• Congenital heart disease34 works · 4 trials
• Kidney cancer32 works · 4 trials
• Lupus (SLE)31 works · 6 trials
• Acute myeloid leukaemia31 works · 6 trials
• Head and neck cancer30 works · 4 trials
• Depression30 works · 2 trials